Consulting company that offers translational toxicology solutions to pharma and biotech

Overseeing the company´s R&D programs in liver safety, liver disease, islet biology and oncology. Development of specific applications as needed by customers. Development of specific DILI applications for each phase of the Pharma life cycle from Discovery to Clinics. Founder and leader of the international X-Species DILI validation consortium with 9 industry partners from Pharma and Technology.

Setting-up a global Mechanistic and Investigative Toxicology organization at 3 sites with the scientific focus in Predictive Toxicology, Biomarker and Mechanistic Toxicology

Discovery and Investigative Safety (DIS) within Preclinical Safety Department (PCS). Conducting complex mechanistic in vivo and in vitro toxicity studies. Safety profiling of developmental compounds and drugs in all development phases. Safety biomarker discovery and validation.

Increasing responsibility as Group Head, Section Head and Global Section Head within the field of Investigative Toxicology/Preclinical Safety and Biomarker Development Department at Novartis Pharma AG Basel. In parallel Part Time Project Representative (PTR) to support early compound development.

Setting-up of various In Vitro Toxicology models and In Vitro Toxicity Screens, particularly for liver, kidney and heart.